Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Janssen licenses cancer drug from Yuhan
by Ryan Cross
November 8, 2018
| A version of this story appeared in
Volume 96, Issue 45
Janssen is paying the South Korean drugmaker Yuhan $50 million to develop its drug candidate lazertinib, which is being tested in people with non-small-cell lung cancers, including ones with brain metastases. Yuhan could receive up to $1.2 billion in future payments from Janssen. Lazertinib is an epithelial growth factor tyrosine-kinase inhibitor. Another drug of that class, AstraZeneca’s Tagrisso, was approved in the U.S. in April and is expected to bring in billions of dollars.
CORRECTION: On Nov. 14, 2018, this story was updated to correct the structure of lazertinib. The original structure was missing a nitrogen.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X